| answer text |
<p>As an independent body, it is for the National Institute for Health and Care Excellence
(NICE), in consultation with stakeholders, to consider NHS England’s request to defer
implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic
hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the
funding period and we understand that NICE expects to publish the outcome of that
consultation, along with its final draft guidance on sofosbuvir, later this month.
The Department’s response to the consultation will be published alongside other stakeholders’
comments. We are confident that NICE will carefully consider all the comments it has
received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently
expects to publish its final guidance on sofosbuvir in February 2015, although this
is subject to any appeals being received.</p><p> </p>
|
 |
